Phase 1 Primary Peritoneal Carcinoma Clinical Trials
10 recruitingPhase 1
What is a Phase 1 trial?
Phase 1 trials test a new treatment in a small group of people for the first time. The primary goal is to evaluate safety, determine a safe dosage range, and identify side effects. These studies typically enroll 20 to 80 participants.
Showing 1–10 of 10 trials
Recruiting
Phase 1
Serial Imaging of the Novel Radiotracer [^18F] FLuorthanatrace ([^18F] FTT) by PET/CTF
Breast CarcinomaOvarian CarcinomaPrimary Peritoneal Carcinoma+5 more
M.D. Anderson Cancer Center300 enrolled1 locationNCT03604315
Recruiting
Phase 1
Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers
Metastatic Endometrial CarcinomaStage III Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8Stage IV Uterine Corpus Carcinoma or Carcinosarcoma AJCC v8+8 more
National Cancer Institute (NCI)42 enrolled6 locationsNCT05691504
Recruiting
Phase 1Phase 2
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Endometrial CancerPrimary Peritoneal CarcinomaNon-small Cell Lung Cancer+6 more
Genmab764 enrolled66 locationsNCT05579366
Recruiting
Phase 1Phase 2
Vaccine Therapy Plus Pembrolizumab in Treating Advanced Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic40 enrolled3 locationsNCT05920798
Recruiting
Phase 1Phase 2
Dual-Targeting CAR-NK Cells for Recurrent Ovarian Cancer (MSLN, FRα, MUC16)
Primary Peritoneal CarcinomaFallopian Tube CarcinomaEpithelial Ovarian Cancer+1 more
Beijing Biotech36 enrolled1 locationNCT07480954
Recruiting
Phase 1
MUC1-Activated T Cells for the Treatment of Relapsed and Resistant Ovarian Cancer
Recurrent Ovarian CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Primary Peritoneal Carcinoma+13 more
Mayo Clinic12 enrolled1 locationNCT06483048
Recruiting
Phase 1
Talazoparib and Radiation Therapy in Treating Patients With Locally Recurrent Gynecologic Cancers
Malignant Female Reproductive System NeoplasmStage IV Cervical Cancer AJCC v8Stage IVA Cervical Cancer AJCC v8+22 more
M.D. Anderson Cancer Center24 enrolled2 locationsNCT03968406
Recruiting
Phase 1
A Study to Learn if 27T51, a Mucin-16 (MUC16) Protein Targeting Immune Cell Therapy, Administered Alone or in Combination is Safe and How Well it Works for Adult Participants With Recurrent or Treatment Resistant Ovarian Cancers
Primary Peritoneal CarcinomaFallopian Tube CancerEpithelial Ovarian Cancer
Regeneron Pharmaceuticals90 enrolled5 locationsNCT06469281
Recruiting
Phase 1
Phase I Study of Tumor Treating Fields (TTF) in Combination With Cabozantinib or With Pembrolizumab and Nab-Paclitaxel in Patients With Advanced Solid Tumors Involving the Abdomen or Thorax
Malignant Solid NeoplasmAnatomic Stage III Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8+71 more
M.D. Anderson Cancer Center43 enrolled1 locationNCT05092373
Recruiting
Phase 1
Determining the Biodistribution of an Imaging Tracer (68Ga-FAPi-46) in Patients With Solid Tumors or Hematologic Cancers
Breast CarcinomaUrothelial CarcinomaOvarian Carcinoma+31 more
Jonsson Comprehensive Cancer Center30 enrolled1 locationNCT07118176